bêta
IA Trial Radar
L'essai clinique NCT06018194 pour Maladie de l'artère coronaire est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte

ELUCIDATE FFRct Study

En recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'étude clinique NCT06018194 est un essai observationnel pour Maladie de l'artère coronaire. Son statut actuel est : en recrutement. L'étude a débuté le 1 septembre 2023 et vise à recruter 350 participants. Dirigé par Elucid Bioimaging Inc., l'essai devrait être terminé d'ici le 31 juillet 2024. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 20 février 2024.
Résumé succinct
The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR).

Researchers will compare the Elucid plaque-based FFRct analysis to invasively measured FFR in patients who have previously undergone CCTA and invasively assessed FFR.

Description détaillée
Invasive fractional flow reserve is a clinically validated measure of lesion-specific ischemia and is preferred over visual estimation of diameter stenosis for clinical decision-making regarding coronary revascularization in patients with stable clinical presentations. Fractional flow reserve derived from coronary computed tomography angiography (FFRct) using computational fluid dynamic (CFD)-based software has been shown to be a reasonably accurate estimate of invasive FFR and is included in contemporary guidelines as a decision-tool for management of patients with intermediate stenosis on CCTA. However, CFD-based FFRct is calculated based predominately on detailed coronary lumen geometry. It is understood that the burden and type of coronary atherosclerosis, in addition to lumen geometry, significantly impacts the vasodilatory capacity of the coronary endothelium.

Preliminary studies suggest that invasive FFR can be accurately estimated based on the quantification of coronary plaque burden and the assessment of plaque composition. Previously, the investigators have demonstrated that a novel plaque-based FFRct approach, using a histologically validated software (ElucidVivoTM) for the measurement of plaque morphology (volume, plaque risk characteristics, and stenosis) to train a deep-learning model, was shown to be accurate and superior to lumen stenosis for predicting invasive FFR in a single-site feasibility study.

In this study, the investigators seek to assess the diagnostic accuracy of the Elucid plaque-based FFRct software to estimate invasive FFR in patients at multiple centers.

Titre officiel

The ELUCIDATE FFRct Study

Conditions
Maladie de l'artère coronaire
Publications
Articles scientifiques et travaux de recherche publiés sur cet essai clinique:
Autres identifiants de l'essai
  • 3-ST-03-03
Numéro NCT
Date de début (réel)
2023-09-01
Dernière mise à jour publiée
2024-02-20
Date de fin (estimée)
2024-07-31
Inscription (estimée)
350
Type d'essai
Observationnel
Statut
En recrutement
Mots clés
coronary computed tomographic angiography
coronary CTA
cardiac CT
fractional flow reserve
plaque
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
Low FFR
Invasive FFR \<= 0.80
Elucidvivo
Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
High FFR
Invasive FFR \> 0.80
Elucidvivo
Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
Critère principal d'évaluation
Critères d'évaluationDescription de critèresPériode
Sensitivity of FFRct versus invasive FFR for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Specificity of FFRct versus invasive FFR for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Critère secondaire d'évaluation
Critères d'évaluationDescription de critèresPériode
Sensitivity of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Specificity of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Area under the receiver-operating characteristic curve (AUC) of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Area under the receiver-operating characteristic curve (AUC) of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Accuracy of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Accuracy of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Negative predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Negative predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Positive predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Positive predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Critères d'éligibilité

Âges éligibles
Adulte, Adulte âgé
Âge minimum
18 Years
Sexes éligibles
Tous

- Adults >=18 years with at least one 30-90% stenosis on CCTA (>64- detector row) performed within 60 days of undergoing invasive FFR.

  • History of coronary revascularization with coronary artery bypass graft (CABG) surgery and/or percutaneous coronary intervention (PCI) (stent or balloon angioplasty) prior to CCTA and invasive FFR.
  • History of myocardial infarction prior to CCTA and invasive FFR.
  • Known complex congenital heart disease.
  • Existing pacemaker or internal defibrillator lead implantation(s).
  • Existing prosthetic heart valve.
  • Absence of CCTA Digital Imaging and Communications in Medicine (DICOM) data for analysis.
  • Absence of invasive coronary angiography imaging or adequate description defining the position of the invasive FFR wire location.
  • Poor CCTA image quality that does not meet Elucid image processing requirements for plaque and FFRct.
  • Absence of study date for CCTA or invasive FFR.
  • Interval clinical myocardial infarction, diagnosis of decompensated heart failure, stroke, or coronary revascularization procedure between CCTA and invasive FFR.
  • Non-diagnostic CCTA or invasive FFR. Studies where the results of the study were deemed non-diagnostic for clinical decision-making will be excluded.
  • CCTA or invasive FFR studies performed prior to 1 January 2016.
Elucid Bioimaging Inc. logoElucid Bioimaging Inc.
Lundquist Institute at Harbor-UCLA Medical Center logoLundquist Institute at Harbor-UCLA Medical Center
Contact central de l'essai
Contact: Todd C Villines, MD, 978-468-0508, [email protected]
Contact: John Aluru, MBBS, 978-468-0508, [email protected]
9 Centres de l'essai dans 1 pays

California

Cardiovascular Medical Group of Southern California, Beverly Hills, California, 90210, United States
Ronald P Karlsberg, MD, Contact
Pas encore en recrutement

Georgia

Piedmont Healthcare, Atlanta, Georgia, 30309, United States
Venkateshwar Polsani, MD, Contact
Pas encore en recrutement

Indiana

Parkview Health, Fort Wayne, Indiana, 46845, United States
Dustin Thomas, MD, Contact
Pas encore en recrutement

Kansas

Midwest Heart and Vascular Specialists, Overland Park, Kansas, 66211, United States
Stephen A Bloom, MD, Contact
En recrutement

New Jersey

Valley Health System, Ridgewood, New Jersey, 07450, United States
Himanshu Gupta, MD, Contact
Pas encore en recrutement

Ohio

Cleveland Clinic, Cleveland, Ohio, 44195, United States
Milind Desai, MD, MBA, Contact
Pas encore en recrutement

Tennessee

Centennial Heart, Nashville, Tennessee, 37203, United States
David Huneycutt, MD, Contact
Pas encore en recrutement
Ascension Medical Group, Nashville, Tennessee, 37205, United States
Andrew O Zurich, MD, Contact
Pas encore en recrutement

Virginia

University of Virginia, Charlottesville, Virginia, 22908, United States
Patricia Rodriguez-Lozano, MD, Contact
En recrutement